CPT-11

DRUG12 trials

Sponsors

University of Chicago, Ohio State University Comprehensive Cancer Center, Dana-Farber Cancer Institute, UNC Lineberger Comprehensive Cancer Center, M.D. Anderson Cancer Center

Conditions

Advanced Gastrointestinal TumorsBreast CancerCancer of StomachCervical CancerColorectal CancerColorectal NeoplasmsDigestive System NeoplasmsEsophageal Cancer

Phase 1

Taxotere, Cisplatin, and CPT-11 in Advanced Solid Tumor Malignancies

CompletedNCT00251407

Dana-Farber Cancer InstituteSolid Tumor

Start: 1999-09-30End: 2009-04-30Updated: 2012-08-09

CPT-11/Cisplatin and Celecoxib With Radiation Therapy for Patients With Unresectable Non-Small Cell Lung Cancer (NSCLC)

CompletedNCT00346801

M.D. Anderson Cancer CenterLung Cancer

Start: 2003-09-30Updated: 2012-10-22

A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.

CompletedNCT01916447

Taiho Oncology, Inc.Advanced Gastrointestinal Tumors

Start: 2013-09-30End: 2017-09-30Target: 65Updated: 2024-09-05

Phase 2

Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer

CompletedNCT00003950

University of ChicagoColorectal Cancer

Start: 2000-01-31End: 2005-01-31Updated: 2014-03-07

Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer

CompletedNCT00201747

Ohio State University Comprehensive Cancer CenterCancer of Stomach, Esophageal Cancer, Esophagus Cancer +1

Start: 2001-09-30End: 2010-02-28Updated: 2017-12-06

Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim

CompletedNCT00280787

UNC Lineberger Comprehensive Cancer CenterNon Small Cell Lung Cancer

Start: 2003-11-30End: 2010-10-31Updated: 2013-02-05

Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas

CompletedNCT00412542

M.D. Anderson Cancer CenterGlioblastoma Multiforme, Glioma

Start: 2003-10-31End: 2009-10-31Updated: 2012-02-28

A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain

TerminatedNCT00476827

Duke UniversityBreast Cancer

Start: 2007-05-31End: 2011-05-31Updated: 2013-07-17

CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas

TerminatedNCT03387592

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSNeuroendocrine Carcinoma

Start: 2017-03-06End: 2022-02-28Updated: 2025-03-10

Phase 3

A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC

RecruitingNCT03303495

Sun Yat-sen UniversityColorectal Neoplasms, Digestive System Neoplasms, Gastrointestinal Neoplasms +2

Start: 2011-11-14End: 2026-12-31Target: 280Updated: 2026-06-05

Phase 4

Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer

Wang JufengGastric Cancer

Start: 2014-08-31End: 2018-08-31Target: 900Updated: 2015-03-30

Unknown Phase

An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid Tumors

CompletedNCT01040312

Daiichi Sankyo Co., Ltd.Cervical Cancer, Gastric Cancer (Inoperable and Recurrent), Non-small Cell Lung Cancer +2

Start: 2009-10-15End: 2015-09-02Updated: 2019-05-23

Related Papers

A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas

European Journal of Cancer2024-05-2510 citations

Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol

BMJ Open2020-07-0120 citations

A phase II study of trifluridine/tipiracil, irinotecan, and bevacizumab in pretreated metastatic colorectal cancer (TABAsCO).

Journal of Clinical Oncology2020-02-01

A phase I expansion study of trifluridine and tipiracil (FTD/TPI) in combination with irinotecan (IRI) and bevacizumab (BEV) in patients with metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology2018-05-20